Generic placeholder image

Current Vascular Pharmacology

Editor-in-Chief

ISSN (Print): 1570-1611
ISSN (Online): 1875-6212

Drug-Induced Pulmonary Hypertension in Newborns: A Review.

Author(s): Paolo Silvani and Anna Camporesi

Volume 5 , Issue 2 , 2007

Page: [129 - 133] Pages: 5

DOI: 10.2174/157016107780368316

Price: $65

Abstract

Persistent pulmonary hypertension (PPHN) is a disease characterised by the disruption of the transition from fetal to neonatal circulation with the persistence of high pulmonary vascular resistances and right-to left shunting. This condition, occurring in about 1-2 newborns per 1000 live births, causes severe hypoxemia. Despite significant improvements in treatment, the mortality of PPHN varies from 10 to 20 % of affected newborns. Pulmonary hypertension is frequently observed in some cardiac malformation and in congenital diaphragmatic hernia, in meconium aspiration syndrome, neonatal sepsis, podalic presentation and male sex. Maternal risk factors are tobacco smoking, cesarean section, low socioeconomic conditions, diabetes and urinary infections. Another predisposing condition is antenatal or postnatal exposure to some drugs. The medications involved in drug-induced pulmonary hypertension and the mechanisms involved are reviewed.

Keywords: Pulmonary hypertension, newborn, persistent pulmonary hypertension of the newborn, non-steroidal antiinflammatory agents, serotonin-reuptake inhibitors, octreotide, diazoxide


Rights & Permissions Print Export Cite as
© 2022 Bentham Science Publishers | Privacy Policy